APO RESEARCH · REPORT
Vaccine
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and keep a record of it so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or "wild" pathogen), or therapeutic (e.g., vaccines against cancer are being investigated).
Product & engineering
Understand the product.
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and keep a record of it so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or "wild" pathogen), or therapeutic (e.g., vaccines against cancer are being investigated).
Selected research
Industry Research
Vaccine Industry Research Report 2026
Market perspective
A vaccine is a biological preparation that provides active acquired immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as a threat, destroy it, and keep a record of it so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. Vaccines can be prophylactic (example: to prevent or ameliorate the effects of a future infection by any natural or "wild" pathogen), or therapeutic (e.g., vaccines against cancer are being investigated).
The global Vaccine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Vaccine market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Vaccine market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Vaccine include AstraZeneca, BioNTech, Boehringer-Ingelheim, CCBIO, CSL, CureVac, Elanco, GSK and Hulan Bio, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Read the full market overview
Report Scope
This report quantifies the global Vaccine market in terms of revenue (US$ million) and, where applicable, service volume (M Dose), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/M Dose) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Vaccine.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vaccine Market by Company
AstraZeneca
BioNTech
Boehringer-Ingelheim
CCBIO
CSL
CureVac
Elanco
GSK
Hulan Bio
Indian Immunologicals
Merck
Minhai Biotechnology
Mitsubishi Tanabe Pharma
Moderna Therapeutics
Mylan
Plumbline Life Sciences
Sanofi
Translate Bio
Walvax Biotechnology
Wuhan Institute of Biological Products
Zoties
Vaccine Segment by Type
Varicella Vaccine
Influenza Vaccine
Polio Vaccine
Hepatitis A Vaccine
Rabies Vaccine
BCG Vaccine
Hepatitis B
Pertussis, Diphtheria, Tetanus
Pneumococcal
Others
Vaccine Segment by Application
For Adult
For Child
Vaccine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Vaccine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Varicella Vaccine
- Influenza Vaccine
- Polio Vaccine
- Hepatitis A Vaccine
- Rabies Vaccine
- BCG Vaccine
- Hepatitis B
- Pertussis, Diphtheria, Tetanus
- Pneumococcal
- Others
Applications
- For Adult
- For Child
Companies covered
- AstraZeneca
- BioNTech
- Boehringer-Ingelheim
- CCBIO
- CSL
- CureVac
- Elanco
- GSK
- Hulan Bio
- Indian Immunologicals
- Merck
- Minhai Biotechnology
- Mitsubishi Tanabe Pharma
- Moderna Therapeutics
- Mylan
- Plumbline Life Sciences
- Sanofi
- Translate Bio
- Walvax Biotechnology
- Wuhan Institute of Biological Products
- Zoties
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Vaccine by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Varicella Vaccine
- 2.2.3 Influenza Vaccine
- 2.2.4 Polio Vaccine
- 2.2.5 Hepatitis A Vaccine
- 2.2.6 Rabies Vaccine
- 2.2.7 BCG Vaccine
- 2.2.8 Hepatitis B
- 2.2.9 Pertussis, Diphtheria, Tetanus
- 2.2.10 Pneumococcal
- 2.2.11 Others
- 2.3 Vaccine by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 For Adult
- 2.3.3 For Child
- 2.4 Assumptions and Limitations
3 Vaccine Breakdown Data by Type
- 3.1 Global Vaccine Historic Market Size by Type (2021-2026)
- 3.2 Global Vaccine Forecasted Market Size by Type (2027-2032)
4 Vaccine Breakdown Data by Application
- 4.1 Global Vaccine Historic Market Size by Application (2021-2026)
- 4.2 Global Vaccine Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Vaccine Market Perspective (2021-2032)
- 5.2 Global Vaccine Growth Trends by Region
- 5.2.1 Global Vaccine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Vaccine Historic Market Size by Region (2021-2026)
- 5.2.3 Vaccine Forecasted Market Size by Region (2027-2032)
- 5.3 Vaccine Market Dynamics
- 5.3.1 Vaccine Industry Trends
- 5.3.2 Vaccine Market Drivers
- 5.3.3 Vaccine Market Challenges
- 5.3.4 Vaccine Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Vaccine Players by Revenue
- 6.1.1 Global Top Vaccine Players by Revenue (2021-2026)
- 6.1.2 Global Vaccine Revenue Market Share by Players (2021-2026)
- 6.2 Global Vaccine Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Vaccine Head Office and Area Served
- 6.4 Global Vaccine Players, Product Type & Application
- 6.5 Global Vaccine Manufacturers Established Date
- 6.6 Global Vaccine Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Vaccine Market Size (2021-2032)
- 7.2 North America Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Vaccine Market Size by Country (2021-2026)
- 7.4 North America Vaccine Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Vaccine Market Size (2021-2032)
- 8.2 Europe Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Vaccine Market Size by Country (2021-2026)
- 8.4 Europe Vaccine Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Vaccine Market Size (2021-2032)
- 9.2 Asia-Pacific Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Vaccine Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Vaccine Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Vaccine Market Size (2021-2032)
- 10.2 South America Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Vaccine Market Size by Country (2021-2026)
- 10.4 South America Vaccine Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Vaccine Market Size (2021-2032)
- 11.2 Middle East & Africa Vaccine Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Vaccine Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Vaccine Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 AstraZeneca
- 12.1.1 AstraZeneca Company Information
- 12.1.2 AstraZeneca Business Overview
- 12.1.3 AstraZeneca Revenue in Vaccine Business (2021-2026)
- 12.1.4 AstraZeneca Vaccine Product Portfolio
- 12.1.5 AstraZeneca Recent Developments
- 12.2 BioNTech
- 12.2.1 BioNTech Company Information
- 12.2.2 BioNTech Business Overview
- 12.2.3 BioNTech Revenue in Vaccine Business (2021-2026)
- 12.2.4 BioNTech Vaccine Product Portfolio
- 12.2.5 BioNTech Recent Developments
- 12.3 Boehringer-Ingelheim
- 12.3.1 Boehringer-Ingelheim Company Information
- 12.3.2 Boehringer-Ingelheim Business Overview
- 12.3.3 Boehringer-Ingelheim Revenue in Vaccine Business (2021-2026)
- 12.3.4 Boehringer-Ingelheim Vaccine Product Portfolio
- 12.3.5 Boehringer-Ingelheim Recent Developments
- 12.4 CCBIO
- 12.4.1 CCBIO Company Information
- 12.4.2 CCBIO Business Overview
- 12.4.3 CCBIO Revenue in Vaccine Business (2021-2026)
- 12.4.4 CCBIO Vaccine Product Portfolio
- 12.4.5 CCBIO Recent Developments
- 12.5 CSL
- 12.5.1 CSL Company Information
- 12.5.2 CSL Business Overview
- 12.5.3 CSL Revenue in Vaccine Business (2021-2026)
- 12.5.4 CSL Vaccine Product Portfolio
- 12.5.5 CSL Recent Developments
- 12.6 CureVac
- 12.6.1 CureVac Company Information
- 12.6.2 CureVac Business Overview
- 12.6.3 CureVac Revenue in Vaccine Business (2021-2026)
- 12.6.4 CureVac Vaccine Product Portfolio
- 12.6.5 CureVac Recent Developments
- 12.7 Elanco
- 12.7.1 Elanco Company Information
- 12.7.2 Elanco Business Overview
- 12.7.3 Elanco Revenue in Vaccine Business (2021-2026)
- 12.7.4 Elanco Vaccine Product Portfolio
- 12.7.5 Elanco Recent Developments
- 12.8 GSK
- 12.8.1 GSK Company Information
- 12.8.2 GSK Business Overview
- 12.8.3 GSK Revenue in Vaccine Business (2021-2026)
- 12.8.4 GSK Vaccine Product Portfolio
- 12.8.5 GSK Recent Developments
- 12.9 Hulan Bio
- 12.9.1 Hulan Bio Company Information
- 12.9.2 Hulan Bio Business Overview
- 12.9.3 Hulan Bio Revenue in Vaccine Business (2021-2026)
- 12.9.4 Hulan Bio Vaccine Product Portfolio
- 12.9.5 Hulan Bio Recent Developments
- 12.10 Indian Immunologicals
- 12.10.1 Indian Immunologicals Company Information
- 12.10.2 Indian Immunologicals Business Overview
- 12.10.3 Indian Immunologicals Revenue in Vaccine Business (2021-2026)
- 12.10.4 Indian Immunologicals Vaccine Product Portfolio
- 12.10.5 Indian Immunologicals Recent Developments
- 12.11 Merck
- 12.11.1 Merck Company Information
- 12.11.2 Merck Business Overview
- 12.11.3 Merck Revenue in Vaccine Business (2021-2026)
- 12.11.4 Merck Vaccine Product Portfolio
- 12.11.5 Merck Recent Developments
- 12.12 Minhai Biotechnology
- 12.12.1 Minhai Biotechnology Company Information
- 12.12.2 Minhai Biotechnology Business Overview
- 12.12.3 Minhai Biotechnology Revenue in Vaccine Business (2021-2026)
- 12.12.4 Minhai Biotechnology Vaccine Product Portfolio
- 12.12.5 Minhai Biotechnology Recent Developments
- 12.13 Mitsubishi Tanabe Pharma
- 12.13.1 Mitsubishi Tanabe Pharma Company Information
- 12.13.2 Mitsubishi Tanabe Pharma Business Overview
- 12.13.3 Mitsubishi Tanabe Pharma Revenue in Vaccine Business (2021-2026)
- 12.13.4 Mitsubishi Tanabe Pharma Vaccine Product Portfolio
- 12.13.5 Mitsubishi Tanabe Pharma Recent Developments
- 12.14 Moderna Therapeutics
- 12.14.1 Moderna Therapeutics Company Information
- 12.14.2 Moderna Therapeutics Business Overview
- 12.14.3 Moderna Therapeutics Revenue in Vaccine Business (2021-2026)
- 12.14.4 Moderna Therapeutics Vaccine Product Portfolio
- 12.14.5 Moderna Therapeutics Recent Developments
- 12.15 Mylan
- 12.15.1 Mylan Company Information
- 12.15.2 Mylan Business Overview
- 12.15.3 Mylan Revenue in Vaccine Business (2021-2026)
- 12.15.4 Mylan Vaccine Product Portfolio
- 12.15.5 Mylan Recent Developments
- 12.16 Plumbline Life Sciences
- 12.16.1 Plumbline Life Sciences Company Information
- 12.16.2 Plumbline Life Sciences Business Overview
- 12.16.3 Plumbline Life Sciences Revenue in Vaccine Business (2021-2026)
- 12.16.4 Plumbline Life Sciences Vaccine Product Portfolio
- 12.16.5 Plumbline Life Sciences Recent Developments
- 12.17 Sanofi
- 12.17.1 Sanofi Company Information
- 12.17.2 Sanofi Business Overview
- 12.17.3 Sanofi Revenue in Vaccine Business (2021-2026)
- 12.17.4 Sanofi Vaccine Product Portfolio
- 12.17.5 Sanofi Recent Developments
- 12.18 Translate Bio
- 12.18.1 Translate Bio Company Information
- 12.18.2 Translate Bio Business Overview
- 12.18.3 Translate Bio Revenue in Vaccine Business (2021-2026)
- 12.18.4 Translate Bio Vaccine Product Portfolio
- 12.18.5 Translate Bio Recent Developments
- 12.19 Walvax Biotechnology
- 12.19.1 Walvax Biotechnology Company Information
- 12.19.2 Walvax Biotechnology Business Overview
- 12.19.3 Walvax Biotechnology Revenue in Vaccine Business (2021-2026)
- 12.19.4 Walvax Biotechnology Vaccine Product Portfolio
- 12.19.5 Walvax Biotechnology Recent Developments
- 12.20 Wuhan Institute of Biological Products
- 12.20.1 Wuhan Institute of Biological Products Company Information
- 12.20.2 Wuhan Institute of Biological Products Business Overview
- 12.20.3 Wuhan Institute of Biological Products Revenue in Vaccine Business (2021-2026)
- 12.20.4 Wuhan Institute of Biological Products Vaccine Product Portfolio
- 12.20.5 Wuhan Institute of Biological Products Recent Developments
- 12.21 Zoties
- 12.21.1 Zoties Company Information
- 12.21.2 Zoties Business Overview
- 12.21.3 Zoties Revenue in Vaccine Business (2021-2026)
- 12.21.4 Zoties Vaccine Product Portfolio
- 12.21.5 Zoties Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst